Gabay Avraham 4

What Happened
Avraham Gabay, Chief Financial Officer of Oramed Pharmaceuticals, sold 73,360 shares on July 1, 2026. The sales generated approximately $330,744, reported at a weighted-average price of $4.51 per share. This was a sale (not a purchase), often a routine disposition rather than an indication of company outlook.

Key Details

• Transaction date: 2026-07-01; Form 4 filed 2026-07-02 (timely filing).
• Transaction type/code: Sale (S) — open market disposition.
• Shares sold: 73,360; weighted-average price reported: $4.51; total proceeds ≈ $330,744.
• Price range: sales occurred across multiple trades at prices from $4.255 to $4.750 (footnote). The filer can provide a breakdown of quantities at each price on request.
• 10b5-1 plan: Sales were made pursuant to a Rule 10b5-1 trading plan adopted March 30, 2026 (footnote).
• Shares owned after transaction: not provided in the details you supplied.

Context
Trades under a 10b5-1 plan are pre-arranged and executed according to a preset schedule or formula, which can limit inference about the insider’s timing or private knowledge. No conclusions about the company’s prospects should be drawn from this single, planned sale.